Athersys (ATHX) Reports Q2, Provides Updates

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. META
6. SPY
7. INTC
8. JBLU
9. AAPL
10. NVDA

Go back to Athersys (ATHX) Reports Q2, Provides Updates

Athersys Reports Second Quarter 2023 Financial Results and Business Highlights

August 16, 2023 5:01 PM EDT

CLEVELAND--(BUSINESS WIRE)-- Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and six months ended June 30, 2023 and provided a business update.

Second Quarter 2023 and Recent Corporate and Operational Highlights:

Nominated healthcare executive and strategy consultant Neema Mayhugh, Ph.D. to the Companys Board of Directors Surpassed two-thirds patient enrollment in the MASTERS-2 clinical trial with MultiStem for ischemic stroke Completed Memorandum of Understanding with Healios to provide... More